What bacteria does Zerbaxa cover?
Zerbaxa has broad activity against gram-negative bacteria, including Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa, as well as against gram positives including Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus.
What does Avycaz cover?
Avycaz is active only against gram-negative bacteria, but is unique in its ability to target carbapenemases. In addition to acting on gram-negative bacteria, Zerbaxa also attacks some anaerobes and some gram-positive bacteria.
What is Zerbaxa cost?
The cost for Zerbaxa intravenous powder for injection (1 g-0.5 g) is around $1,317 for a supply of 10 powder for injection, depending on the pharmacy you visit….Intravenous Powder For Injection.
| Quantity | Per unit | Price |
|---|---|---|
| 10 | $131.68 | $1,316.80 |
When do you take Zerbaxa?
ZERBAXA is indicated for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella …
What does Ceftolozane tazobactam treat?
The combination of ceftolozane and tazobactam is used to treat certain infections including urinary tract infections and infections of the abdomen (stomach area). It is also used to treat certain types of pneumonia that developed in people who are on ventilators or who were in a hospital.
How is Zerbaxa administered?
The recommended dosage regimen of ZERBAXA (ceftolozane/tazobactam) for Injection is 1.5 g (1 g/0.5 g) administered every 8 hours by intravenous infusion over 1 hour in patients 18 years or older and with normal renal function or mild renal impairment.
Does Zerbaxa cover Enterococcus?
NOT ACTIVE against serine carbapenemases (e.g. KPCs or MBLs), most anaerobic bacteria, Staphylococcus spp., and Enterococcus spp.
How much does Zerbaxa cost?
What does Zerbaxa stand for?
FDA approves ceftolozane/tazobactam (Zerbaxa); 4th new antibiotic in 2014. The drug will be marketed as Zerbaxa by the pharmaceutical company Cubist. Ceftolozane is a novel cephalosporin, combined with the existing β-lactamase inhibitor tazobactam in the new product. Zerbaxa has broad activity against gram-negative bacteria,…
When was Zerbaxa approved by FDA?
Zerbaxa’s approval was the 4th antibiotic approved by the FDA in 2014, after a long dry spell during which many pharmaceutical companies had largely abandoned the antibiotics market.
Can Zerbaxa be used to treat ventilator-associated pneumonia?
Trials testing Zerbaxa for ventilator-associated pneumonia are in process. Zerbaxa’s approval was the 4th antibiotic approved by the FDA in 2014, after a long dry spell during which many pharmaceutical companies had largely abandoned the antibiotics market.
What are the beta-lactamases that Zerbaxa does not work against?
Zerbaxa demonstrated in vitro activity against Enterobacteriaceae in the presence of some extended-spectrum beta-lactamases (ESBLs) and other beta-lactamases of the following groups: TEM, SHV, CTX-M, and OXA. Zerbaxa is not active against bacteria that produce serine carbapenemases [ K. pneumoniae carbapenemase (KPC)], and metallo-beta-lactamases.